A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations. ...
Jan 20, 2026
0
10
Mayo Clinic researchers collaborated on a new study led by Eli Lilly showing that the drug abemaciclib improves survival for people with high-risk, early-stage breast cancer.
Oct 23, 2025
0
0
The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Although neoadjuvant chemotherapy together with immunotherapy has been ...
Jan 22, 2025
0
1
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer—as ...
Dec 11, 2024
0
2
The anti-cancer drug abemaciclib (also known as Vernezio) has been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer.
May 7, 2024
0
0
An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute, in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma, has reported ...
Sep 18, 2023
0
0
Abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) is now approved for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, ...
Mar 10, 2023
0
1
